Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Fusion Pharmaceuticals Inc. Common Shares (FUSN)

Biological Products, (no Disgnostic Substances)

https://www.fusionpharma.com

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

270 LONGWOOD ROAD SOUTH
HAMILTON, A6

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/26/2020

Market Cap

1,833,043,000

Shares Outstanding

72,410,000

Weighted SO

72,405,840

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

BCYC --.--%

RLMD --.--%

RAPT --.--%

NAMS --.--%

BCAB --.--%

PASG --.--%

PMVP --.--%

IKNA --.--%

OLMA --.--%

Beta

-0.6920

Last Div

0.0000

Range

2.31-21.6

Chg

0.0300

Avg Vol

1965984

Mkt Cap

1833043000

Exch

NASDAQ

Country

CA

Phone

289 799 0891

DCF Diff

22.4348

DCF

-0.8848

Div Yield

0.0000

P/S

51.3803

EV Multiple

-17.5354

P/FV

7.4654

Div Yield %

0.0000

P/E

-17.3133

PEG

-1.6103

Payout

0.0000

Current Ratio

10.6435

Quick Ratio

10.3909

Cash Ratio

1.3615

DSO

47.8809

DIO

0.0000

Op Cycle

47.8809

DPO

338.7449

CCC

-290.8640

Gross Margin

0.9244

Op Margin

-3.0899

Pretax Margin

-2.9071

Net Margin

-2.9229

Eff Tax Rate

-0.0054

ROA

-0.3220

ROE

-0.4874

ROCE

-0.3637

NI/EBT

1.0054

EBT/EBIT

0.9408

EBIT/Rev

-3.0899

Debt Ratio

0.1667

D/E

0.2232

LT Debt/Cap

0.1704

Total Debt/Cap

0.1825

Int Coverage

-35.0515

CF/Debt

-1.5316

Equity Multi

1.3390

Rec Turnover

7.6231

Pay Turnover

1.0775

Inv Turnover

0.0000

FA Turnover

1.4594

Asset Turnover

0.1102

OCF/Share

-0.9867

FCF/Share

-1.0340

Cash/Share

2.5186

OCF/Sales

-2.3171

FCF/OCF

1.0479

CF Coverage

-1.5316

ST Coverage

-19.2780

CapEx Coverage

-20.8976

Div&CapEx Cov

-20.8976

P/BV

7.4654

P/B

7.4654

P/S

51.3803

P/E

-17.3133

P/FCF

-21.1619

P/OCF

-21.8398

P/CF

-21.8398

PEG

-1.6103

P/S

51.3803

EV Multiple

-17.5354

P/FV

7.4654

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Benzinga Dec 27, 12:42 Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned Benzinga Dec 27, 12:42 Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned Benzinga Dec 27, 12:42 Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned MarketWatch Dec 27, 10:00 2024 could turn into a 'trader's market.' Here's how this strategist says you can make the most of that. MarketWatch Dec 27, 09:47 Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target MarketWatch Dec 27, 09:47 Fusion Pharma climbs as radiopharmaceutical company flagged as potential merger target Benzinga Dec 27, 09:06 Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday Benzinga Dec 20, 14:17 Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside MarketWatch Nov 16, 12:49 10 ‘better values’ in the stock market, selected for the next two years

Revenue Product Segmentation